Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study

AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed. In this study, we aimed to examine the possible effects of once-we...

Full description

Bibliographic Details
Main Authors: Junpei Sanada, Tomohiko Kimura, Masashi Shimoda, Akiko Tomita, Yoshiro Fushimi, Tomoe Kinoshita, Atsushi Obata, Seizo Okauchi, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Endocrinology
Subjects:
DPP-4 inhibitor
weekly GLP-1 receptor activator
dulaglutide
glycemic control
Hba1c
propensity score matching
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.714447/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.714447/full

Similar Items